Abstracts

ACTIVITY OF ECD4-IG AGAINST CCR5 ANTAGONIST-RESISTANT HIV-1

The anti-HIV molecule eCD4-Ig targets CD4 and chemokine coreceptor binding sites of HIV-1 gp120. eCD4-Ig neutralizes a broad range of HIV-1 isolates from various clades, and protects humanized mice and macaques from infection with HIV and SHIV, respectively. To investigate whether eCD4-Ig can neutralize HIV-1 isolates resistant to the CCR5 antagonists maraviroc (MVC) and vicriviroc…

TRIFUNCTIONAL T-CELL ENGAGERS TARGETING PD-1 AND TIGIT IN CHRONIC HIV/SHIV INFECTIONS

Immune checkpoint inhibitors, such as PD-1 and TIGIT, are crucial dysregulators of CD8 T cell function during chronic HIV-1/SIV infections. Importantly, these checkpoint inhibitors are highly expressed on the surface of CD4 T cells that harbor latent HIV. We have previously demonstrated that an anti-HIV/anti-CD3 bispecific T-cell engager (BiTE) can be used to redirect functionally…

COMBINATION OF CRISPR AND LASER ART PREVENTS HIV REBOUND IN HUMANIZED MICE

BACKGROUND: Advances in CRISPR-Cas9gene editing technology and its in vivo delivery by AAV9 vectors together with cell based nanotechnology for long-acting slow effective release antiretroviral therapy (LASER-ART), were used in NSG-CD34 humanized mice to facilitate eradication of HIV-1 in vivo. METHODS: CRISPR-Cas9 proviral DNA excision followed two months of treatment with long-acting slow effective release…

HIV RESERVOIR SIZE IS CORRELATED TO NK-MEDIATED KILLING OF EFFECTOR MEMORY CD4 CELLS

The identification of immune control mechanisms of the viral reservoir might help to develop new strategies to cure HIV. Antibody-dependent cell-mediated cytotoxicity (ADCC), largely mediated by natural killer (NK) cells, has been reported highly relevant to control HIV. However, the role of ADCC-NK at controlling the cells that compose the viral reservoir is currently unknown.…